Floatz logo

Anti-Cd30/Cd16A Monoclonal Antibody Afm13

Peripheral T Cell Lymphoma

Affimed GmbHmonoclonal_antibodyPhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
73/ 100

Competitive context

135 Active assets in the Peripheral T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Inno-206
BeBetter Med Inc
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

Anti-Cd30/Cd16A Monoclonal Antibody Afm13 is also rated in:

mycosis fungoidesDormant
BB
Indicative ·
69 / 100
View asset →
Hodgkins lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →